¡¡¡¡ÐÄѪ¹Ü¼²²¡£¨CVD£©ÊÇΣº¦ÈËÀཡ¿µµÄÍ·ºÅɱÊÖ£¬¶ø¶¯ÂöÖàÑùÓ²»¯£¨AS£©ÊÇÆäºËÐIJ¡Àí»ù´¡¡£¾¡¹ÜËûÍ¡ÀàÒ©ÎïµÈ½µÖ¬ÁÆ·¨ÔÚÁÙ´²ÉϹ㷺ӦÓ㬵«½öÄܽµµÍÔ¼30%µÄCVDʼþ£¬»¼ÕßÈÔÃæÁÙÏÔÖøµÄ¡°²ÐÁô·çÏÕ¡±¡£ÕâÒ»ÖÎÁÆÀ§¾³Ê¹µÃ̽Ë÷½µµ¨¹Ì´¼Ö®ÍâµÄÐͬ¸ÉÔ¤²ßÂÔ£¬³ÉΪµ±Ç°¿¹ASÑо¿ÁìÓòµÄÖØ´óÌôÕ½¡£
¡¡¡¡½üÈÕ£¬Î÷°²½»Í¨´óѧʵÑ鶯ÎïÖÐÐÄÁõ¶÷᪽ÌÊÚÁªºÏÃÀ¹úÃÜÎ÷¸ù´óѧ³ÂÓýÇì½ÌÊÚ¡¢ÎåÒØ´óѧ·¶½ÁؽÌÊÚµÈÍŶӣ¬¿ªÕ¹µÄÒ»Ïî¹ú¼ÊºÏ×÷Ñо¿È¡µÃÁËÍ»ÆÆÐÔ½øÕ¹£ºÆä³É¹ûTripeptide DT-109 (Gly-Gly-Leu) attenuates atherosclerosis and vascular calcification in nonhuman primates·¢±íÔÚNatureµÄ×Ó¿¯Signal Transduction and Targeted Therapy£¨IF=40.8£©¡£¸ÃÑо¿¾ßÓÐÁ½´ó´´Ð£º³É¹¦¹¹½¨Á˸߶ÈÄ£ÄâÈËÀàAS²¡ÀíÌØÕ÷µÄ·ÇÈËÁ鳤ÀදÎïÄ£ÐÍ£»»ùÓڸö¯ÎïÄ£ÐÍ·¢ÏÖÁËÐÂÐÍÈýëÄÒ©ÎïDT-109ͨ¹ý¶à°Ðµã¸ÉÔ¤£¬ÏÔÖø¸ÄÉÆAS²¡±ä£¨Í¼1£©¡£
ͼ1. DT-109ÏÔÖø¸ÄÉÆÊ³Ð·ºïÖ÷¶¯Âö(A, B) ºÍ¹Ú×´¶¯Âö(C) AS²¡ÀíËðÉË¡£
Í»ÆÆÐԳɹûÒ»£ºÏȽøµÄ·ÇÈËÁ鳤ÀදÎïASÄ£ÐÍ
¡¡¡¡Ñо¿ÍŶÓÊ×´ÎÔÚʳзºïµÄÖ÷¶¯ÂöºÍ¹Ú×´¶¯ÂöÖо«×¼ÔÙÏÖÁËÈËÀàASµÄµäÐͲ¡ÀíÌØÕ÷£¬°üÀ¨Ö¬ÖÊÌõÎÆ¡¢ÏËά°ß¿é¡¢ÍíÆÚ¸´ÔÓ²¡±ä£¨È磬»µËÀºËµÄÐγɡ¢µ¨¹Ì´¼½á¾§£©ÒÔ¼°¸Æ»¯µÈ£¨Í¼2£©£¬Ïà¶ÔÓÚ´«Í³Äö³ÝÀදÎïÄ£ÐÍ£¬¸ÃʳзºïÄ£ÐÍÊ×´ÎÍêÕûÄ£ÄâÁËÈËÀàASµÄ²¡ÀíÑݽø¹ý³Ì£¬Í¹ÏÔÁ˸ÃÄ£ÐÍÔÚÑо¿ÈËÀàAS·¢²¡»úÖÆºÍÒ©ÎïɸѡÖжÀÌØ¼ÛÖµ¡£
ͼ2. ʳзºï³ÊÏÖ³öÓëÈËÏàËÆµÄASËðÉ˵äÐÍÌØÕ÷
Í»ÆÆÐԳɹû¶þ£ºDT-109Ë«ÖØ¿¹ASºÍMASH×÷ÓÃ
¡¡¡¡Ñо¿ÍŶӷ¢ÏÖ£¬AS²¡±äÐγÉÓëѪ¹Ü¸Æ»¯Êdz¤ÆÚÖ¬ÖÊ´úлÎÉÂÒ¡¢ÂýÐÔÑ×Ö¢¡¢Ñõ»¯Ó¦¼¤¡¢Æ½»¬¼¡Ï¸°û±íÐÍת»¯µÈ¹²Í¬×÷ÓõĽá¹û¡£ÈýëÄDT-109ͨ¹ý¶à°Ðµã¸ÉÔ¤ÉÏÊö²¡Àí¹ý³Ì£¬Õ¹ÏÖ³öÏÔÖøµÄ¿¹ASÁÆÐ§¡£
¡¡¡¡ÖµµÃÒ»ÌáµÄÊÇ£¬ÔçÔÚ2023Ä꣬Áõ¶÷᪽ÌÊÚÍŶÓÒÑÔÚ¹ú¼Ê¶¥¿¯ Cell Metabolism£¨2023;35:742-757£©±¨µÀÁËDT-109ÔÚ·ÇÈËÁ鳤ÀදÎï´úл¹¦ÄÜÕϰÏà¹ØÖ¬·¾ÐÔ¸ÎÑ×£¨MASH£©ÖеÄÖÎÁÆÇ±Á¦¡£´Ë´ÎÑо¿½øÒ»²½Ö¤ÊµÁ˸ÃÈýëÄÒ©Îï¶ÔASºÍMASHÕâÁ½´ó´úлÐÔ¼²²¡¾ßÓÐÐͬ¸ÉÔ¤×÷Óã¬ÎªÑ°ÕÒ¶à°ÐµãÖÎÁƲßÂÔÌṩÁËÐÂ˼·¡£Ä¿Ç°£¬¸Ã¹ú¼ÊÑо¿ÍŶӼÌÐøÍÆ½øDT-109¿¹²¡»úÖÆÑо¿ºÍÁÙ´²Ç°ÊÔÑ飬ÒÔÆÚΪAS¡¢MASHµÈ¼²²¡µÄ¾«×¼ÖÎÁÆÌṩ¸ü¶à·½°¸¡£
¡¡¡¡ÂÛÎĹ²Í¬µÚÒ»×÷ÕßΪʵÑ鶯ÎïÖÐÐIJ©Ê¿Éú¼ÖÁÖÓ¨ºÍÇüÅôÏ鸱½ÌÊÚ£¬Áõ¶÷᪽ÌÊÚΪĩλͨѶ×÷Õߣ¬³ÂÓýÇì½ÌÊںͷ¶½ÁؽÌÊÚΪ¹²Í¬Í¨Ñ¶×÷Õß¡£ÃÜЪ¸ù´óѧÕż̷æ½ÌÊÚҲΪ±¾Ñо¿×ö³öÁËÖØÒª¹±Ïס£
¡¡¡¡ÎÄÕÂÁ´½Ó£º
https://www.nature.com/articles/s41392-025-02201-2¡£